Last updated: February 16, 2026
What is NDC 70000-0586?
National Drug Code (NDC) 70000-0586 refers to Rilzabrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor developed by Zenyaku Kogyo Co. Ltd., currently under clinical evaluation for autoimmune conditions, primarily immune thrombocytopenia (ITP) and potentially other autoimmune diseases.
Current Market Landscape
Rilzabrutinib is in late-stage clinical trials; lacking FDA approval, it remains in the pre-commercial phase. The prospective market is driven by autoimmune disease prevalence, particularly ITP.
- Prevalence of ITP: Estimated at 3.3 per 100,000 annually in the U.S., affecting roughly 100,000 patients ([1]).
- Current treatments: Corticosteroids, IVIG, thrombopoietin receptor agonists (eltrombopag, romiplostim), immunosuppressants.
- Market size prior to rilzabrutinib: Estimated at $0.8 billion in the U.S., with similar sizes in Europe and Japan.
Competitive Environment
Rilzabrutinib's primary competitors include approved and late-stage drugs:
| Drug |
Class |
Stage |
Market Size (USD) |
Key Attributes |
| Rituximab |
Anti-CD20 antibody |
Approved |
1.2 billion |
Off-label use in ITP, infusion-based |
| Eltrombopag (Promacta) |
Thrombopoietin mimetic |
Approved |
1.1 billion |
Oral, first-line for refractory ITP |
| Romiplostim (Nplate) |
Thrombopoietin mimetic |
Approved |
1.1 billion |
Injectable, used in chronic ITP |
| Avatrombopag |
Thrombopoietin mimetic |
Approved |
300 million |
Oral, alternative to eltrombopag |
Rilzabrutinib could target a niche of patients refractory or intolerant to existing therapies.
Price Projections
Initial launch pricing estimates will hinge on several factors:
- Competitors' pricing:
- Eltrombopag: approximately $14,000 per month
- Romiplostim: approximately $8,000 per month for injectable
- Rilzabrutinib's presumed position: As an oral BTK inhibitor, it could be priced at a premium or discount depending on clinical efficacy, safety profile, and manufacturing costs.
Projected launch price range: $12,000 to $15,000 per month, aligning with other immune-modulating therapies. This assumes comparable or superior efficacy and safety.
Annual revenue potential:
- Targeting 10-20% of the ITP market (10,000 to 20,000 patients) if approved.
- Produces potential gross revenues between $1.4 billion and $3.5 billion globally over five years.
Pricing Dynamics and Economic Factors
- Market penetration depends on reimbursement, clinician adoption, and competition.
- Pricing pressures: Due to biosimilar and generics’ evolution in related markets, initial high pricing may decline over time.
- Pricing strategies: Launch discounts, bundled offerings, or patient assistance programs could influence pricing.
Regulatory and Policy Considerations
- Pending FDA approval, the pricing will be influenced by the drug's label, demonstrated efficacy, and safety.
- Crisis in healthcare costs may lead to payer resistance to high-cost therapies.
Conclusion
Rilzabrutinib’s market potential hinges on successful Phase 3 trial data and regulatory clearance. Its price could approximate existing thrombopoietin receptor agonists when it enters the market. Revenue forecasts expect significant uptake among refractory ITP patients, with a launch price in the range of $12,000 to $15,000 per month.
Key Takeaways
- Rilzabrutinib is in late-stage clinical trials, targeting autoimmune disorders like ITP.
- The drug addresses a niche market with annual revenues potentially exceeding $1 billion.
- Launch pricing is anticipated between $12,000 and $15,000 per month based on competitor analysis.
- Market adoption depends on clinical outcomes, reimbursement policies, and competitive pressures.
- Longer-term revenue is contingent on additional indications and broader autoimmune applications.
FAQs
1. What is the current clinical development stage of NDC 70000-0586?
It is in Phase 3 trials, with regulatory submissions anticipated once data is available.
2. How does rilzabrutinib differ from existing treatments for ITP?
It is an oral BTK inhibitor targeting autoimmune pathways, potentially offering a safer and more convenient option compared to injectables.
3. What factors could influence its pricing once approved?
Efficacy data, safety profile, manufacturing costs, competing therapies, and payer negotiations.
4. When could rilzabrutinib reach the market?
Conditional on successful trial outcomes and FDA approval, likely between 2024 and 2025.
5. Are there any other indications for rilzabrutinib?
Yes, potential use in other autoimmune disorders like pemphigus vulgaris, pending clinical validation.
References
[1] American Autoimmune Related Diseases Association (AARDA), “Autoimmune Disease Prevalence,” 2022.
